Clinical Trial Update: High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD [Phase 1, Phase 2]

View source ↗

Summary

The trial update indicates that the Phase 1/2 study of high-dose post-transplant cyclophosphamide, bortezomib, and sitagliptin for prevention of graft-versus-ho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia Adult
• Acute Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Januvia (sitagliptin)
• Velcade (bortezomib)

Snippet

Sponsor: Indiana University | Conditions: Bone Marrow Transplant Complications, Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN